The innate immune landscape of dMMR/MSI cancers predicts outcome of nivolumab treatment: results from the Drug Rediscovery Protocol.
Laurien J ZeverijnBirgit S GeurtsThomas W BattagliaJ Maxime van Berge HenegouwenGijs F de WitLouisa R HoesHanneke van der WijngaartVincent van den NoortPaul RoepmanWendy W J de LengAnne M L JansenMyriam ChalabiCarla M L van HerpenLot A DevrieseFrans L G ErdkampMariette LabotsMaja J A de JongeEmile D KerverAdriaan D BinsLindsay V M LeekJessica C L NotohardjoAlfonsus J M van den EertweghLodewyk F A WesselsHenk M W VerheulAndré B P van KuilenburgJoris van de HaarEmile E VoestPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Nivolumab proved highly effective in advanced dMMR/MSI tumors. Expression of key innate immune receptors/ligands was the main predictor of good treatment outcome, contrasting findings in melanoma and strengthening the rationale for tumor-type specific biomarkers for guiding immunotherapy.